Dr. Hamdouchi is an accomplished scientific leader in the pharmaceutical industry, with extensive experience in drug discovery & development; medicinal chemistry, diabetes, oncology, neuroscience and anti-infective research; due diligence & external collaborations in USA, Europe and Asia; portfolio enablement & management; mentoring & talent development.
Dr. Hamdouchi earned his doctorate in organic chemistry from Louis Pasteur University in Strasbourg, France. Following postdoctoral fellowships, he joined Eli Lilly & Company in 1995 as a medicinal chemist where he ultimately became a Senior Research Advisor: a high-ranking position in the scientific track of Lilly Research Laboratories in Indianapolis, Indiana. Throughout his 23-year career at Lilly, he oversaw large cross-functional drug discovery and development teams in the USA, Europe, and Asia to advance small molecules from program inception to clinical proof of concept.
In his role as a scientific leader, he championed the creation of multiple drug discovery strategies and was co-inventor of a dozen clinical candidates — these encompassing novel treatments in cancer, diabetes, and in infectious and neurodegenerative diseases. His strong scientific leadership in the broad drug discovery field is recognized internationally, as evidenced by authorship of numerous worldwide patents, peer-reviewed publications, invited lectures, and awards. Dr. Hamdouchi was the winner of prestigious Lilly President’s Scientific Award and Lilly Executive Board Recognition Award.
Furthermore, he was the scientist responsible for Lilly’s external R & D strategy and FIPNet collaborations, with proven success in developing and integrating the Asia and Europe drug discovery model as an effective extension of global US research capabilities. He was instrumental in the creation and expansion of Lilly-Spain research group. In addition, he established and led the first Lilly's R&D outsourced team in Asia capable of executing drug discovery process from target selection through clinical proof-of-concept, delivering 4 high quality clinical candidates. As a result, he developed extensive experience in the creation of new research centers and outsourced teams capable of executing drug discovery processes encompassing the target identification through candidate selection continuum. He also gained business acumen with regard to strategizing, negotiation and implementation to drive effective, collaborative executions with various academic and industrial business partners. As a member of multiple R&D reviewer committees at Eli Lilly and Company, he routinely participated in setting a strategic direction for the company along with governance of the discovery and early clinical development pipeline.
After 23 years of rich experience, He retired from Eli Lilly & Company at the end of 2017. In 2018, he founded Hamdouchi Pharmaceuticals LLC, dedicated to providing advisory & consulting services as well as drug discovery & development courses to academic and industrial life-science organizations of all sizes and locations — ranging from established and fully integrated institutions to start-ups looking for clinical proof of concept. For this new chapter of his scientific life, he is highly motivated to work at the interface of academic-industrial partnerships, including building relationships, strategizing, negotiating, mentoring and creating effective collaborative research environments that stimulate the design and execution of target selection, lead generation, lead optimization, candidate selection, and phase I and II of clinical development. In addition, he is currently an Adjunct Associate Professor at Indiana University School of Medicine where he is contributing to advancement of the science of clinical pharmacology, therapeutics discovery and translational medicine through educational programs and consulting.
Dr. Hamdouchi has flexibility in both language (French, English, Spanish, Arabic and German) and culture to operate successfully in several professional contexts related to the pharmaceutical business.
PUBLICATIONS (10 Selected)
- Structural basis for GPR40 allosteric agonism and incretin stimulation. Ho, Joseph D.; Chau, Betty; Rodgers, Logan; Lu, Frances; Wilbur, Kelly L.; Otto, Keith A.; Chen, Yanyun; Song, Min; Riley, Jonathan P.; Hsiu-Chiung, Yang; Reynolds, Nichole A.; Kahl, Steven D.; Patel Lewis, Anjana; Groshong, Christopher; Madsen, Russell E.; Conners, Kris; Lineswala, Jayana P.; Gheyi, Tarun; Decipulo Saflor, Melbert-Brian; Lee, Matthew R.; Benach, Jordi; Baker, Kenton A.; Montrose-Rafizadeh, Chahrzad; Genin, Michael J.; Reifel Miller, Anne; Hamdouchi, Chafiq. Nature Communications (2018), 9: 1645
- Discovery of LY3104607: A potent and selective GPR40 agonist with optimized pharmacokinetic properties to support once daily oral treatment in patients with type 2 diabetes mellitus. Hamdouchi, Chafiq; Maiti, Pranab; Warshawsky, Alan M.; DeBaillie, Amy C.; Otto, Keith A.; Wilbur, Kelly L.; Kahl, Steven D.; Patel Lewis, Anjana; Cardona, Guemalli R.; Zink, Richard W.; Chen, Keyue; Lineswala, Jayana P.; Neathery, Grace L.; Campbell, Alison N.; Sweetana, Stephanie A.; Cabrera, Over; Ma, Xiaosu; Yumibe, Nathan P.; Diseroad, Benjamin A.; Montrose-Rafizadeh, Chahrzad; Chen, Yanyun; Reifel Miller, Anne. Journal of Medicinal Chemistry (2018), 61(3), 934-945.
- The discovery, preclinical, and early clinical development of potent and selective GPR40 agonists for the treatment of Type 2 diabetes mellitus (LY2881835, LY2922083, and LY2922470). Hamdouchi, Chafiq; Kahl, Steven D.; Patel Lewis, Anjana; Cardona, Guemalli R.; Zink, Richard W.; Chen, Keyue; Eessalu, Thomas E.; Ficorilli, James V.; Marcelo, Marialuisa C.; Otto, Keith A.; Wilbur, Kelly L.; Lineswala, Jayana P.; Piper, Jared L.; Coffey, D. Scott; Sweetana, Stephanie A.; Haas, Joseph V.; Brooks, Dawn A.; Pratt, Edward J.; Belin, Ruth M.; Deeg, Mark A.; Ma, Xiaosu; Cannady, Ellen A.; Johnson, Jason T.; Yumibe, Nathan P.; Chen, Qi; Maiti, Pranab; Montrose-Rafizadeh, Chahrzad; Chen, Yanyun; Reifel, Miller Anne. Journal of Medicinal Chemistry (2016), 59(24), 10891–10916. (ACS Editors’ Choice + Cover Art selection).
- Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors. Bhangoo, Sonia; Ren, Dongjun; Miller, Richard J.; Henry, Kenneth J.; Lineswala, Jayana; Hamdouchi, Chafiq; Li, Baolin; Monahan, Patrick E.; Chan, David M.; Ripsch, Matthew S.; White, Fletcher A. Molecular Pain (2007), 3:38.
- 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. Gehlert, Donald R.; Cippitelli, Andrea; Thorsell, Annika; Le, Anh Dzung; Hipskind, Philip A.; Hamdouchi, Chafiq; Lu, Jianliang; Hembre, Erik J.; Cramer, Jeffrey; Song, Min; McKinzie, David; Morin, Michelle; Ciccocioppo, Roberto; Heilig, Markus. The Journal of neuroscience (2007), 27(10), 2718-2726.
- Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases. Hamdouchi, Chafiq; Zhong, Boyu; Mendoza, Jose; Collins, Elizabeth; Jaramillo, Carlos; De Diego, Jose Eugenio; Robertson, Daniel; Spencer, Charles D.; Anderson, Bryan D.; Watkins, Scott A.; Zhang, Faming; Brooks, Harold B. Bioorganic & Medicinal Chemistry Letters (2005), 15(7), 1943-1947. (Cover Art selection).
- The discovery of a new structural class of cyclin-dependent kinase inhibitors aminoimidazo [1,2-a]pyridines. Hamdouchi, Chafiq; Keyser, Heather; Collins, Elizabeth; Jaramillo, Carlos; De Diego, Jose Eugenio; Spencer, Charles D.; Dempsey, Jack Alan; Anderson, Bryan D.; Leggett, Tillie; Stamm, Nancy B.; Schultz, Richard M.; Watkins, Scott A.; Cocke, Kim; Lemke, Stephanie; Burke, Teresa F.; Beckmann, Richard P.; Dixon, Jeffrey T.; Gurganus, Thomas M.; Rankl, Nancy B.; Houck, Keith A.; Zhang, Faming; Vieth, Michal; Espinosa, Juan; Timm, David E.; Campbell, Robert M.; Patel, Bharvin K. R.; Brooks, Harold B. Molecular Cancer Therapeutics (2004), 3(1), 1-9. (Cover Art selection).
- Imidazo[1,2-b]pyridazines, novel nucleus with potent and broad spectrum activity against human picornaviruses: design, synthesis, and biological evaluation. Hamdouchi, Chafiq; Sanchez-Martinez, Concha; Gruber, Joseph; del Prado, Miriam; Lopez, Javier; Rubio, Almudena; Heinz, Beverly A. Journal of Medicinal Chemistry (2003), 46(20), 4333-4341.
- 2-Amino-3-substituted-6-[(E)-1-phenyl-2-(N-methylcarbamoyl)vinyl]imidazo[1,2-a]pyridines as a novel class of inhibitors of human rhinovirus: stereospecific synthesis and antiviral activity. Hamdouchi, Chafiq; De Blas, Jesus; Del Prado, Mirian; Gruber, Joseph; Heinz, Beverly A.; Vance, Lori. Journal of Medicinal Chemistry (1999), 42(1), 50-59.
- The nature of electron transfer from metal surfaces to the carbon-halogen bond. Walborsky, Harry; Hamdouchi, Chafiq. Journal of the American Chemical Society (1993), 115(14), 6406-8.